Breakthrough status in hand, Prosensa launches $78m IPO

Taking advantage of the US FDA's decision to grant a breakthrough therapy designation for its lead drug candidate drisapersen in partnership with GlaxoSmithKline, Dutch biotechnology firm Prosensa priced its US initial public offering at $13 per share for gross proceeds of $78 million.